The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
Q3 FY25 revenue up 24% to Rs 3,230 crore
EBITDA margins expand to 31.3%
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
In 2023, Endox had revenues of approximately SEK 65 million
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Subscribe To Our Newsletter & Stay Updated
